MedTrace Logo

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

NCT01963481 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-03-17

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.

Conditions

  • Metastatic Beast Cancer

Interventions

DRUG

Exemestane

DRUG

Cyclophosphamide

Sponsors & Collaborators

Principal Investigators

  • Sylvia Adams, MD · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-10-01
Completion
2017-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01963481 on ClinicalTrials.gov